Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing new...
-
SAN DIEGO, Aug. 28, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics, harnessing the...
-
– Resolaris Demonstrated Favorable Safety Profile in Rare Muscular Dystrophy Patients in Extension Studies –– iMod.Fc Program for Interstitial Lung Disease (ILD) on Track to Commence Phase 1 Clinical...
-
SAN DIEGO, Aug. 10, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe,...
-
SAN DIEGO, May 31, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe,...
-
- Poster Presentations to Explore Potential of Augmenting Resokine Pathway in Severe, Rare Pulmonary Diseases with an Immune or Fibrotic Component - - Conference Call and Webcast Featuring Guest...
-
– Announced Promising Top-Line Results from ResolarisTM Phase 1b/2 Trial in Early Onset FSHD –– Preclinical Data from StalarisTM Program to be Presented at American Thoracic Society...
-
- Resolaris Demonstrated Favorable Safety Profile and Promising Signals of Clinical Activity - - Resolaris has FDA Fast Track and Orphan Drug Designation for Limb Girdle Muscular Dystrophy 2B...
-
- 63% of Patients Observed Increased Muscle Strength - - Resolaris Demonstrated a Generally Well-Tolerated Safety Profile in Younger Patient Population - SAN DIEGO, April 24, 2017 (GLOBE NEWSWIRE)...
-
SAN DIEGO, April 10, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe,...